Asset Details
Do you wish to reserve the book?
Effect of dapagliflozin on ventricular repolarization in patients with heart failure with reduced ejection fraction
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of dapagliflozin on ventricular repolarization in patients with heart failure with reduced ejection fraction
Do you wish to request the book?
Effect of dapagliflozin on ventricular repolarization in patients with heart failure with reduced ejection fraction
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of dapagliflozin on ventricular repolarization in patients with heart failure with reduced ejection fraction
2023
Overview
Whether sodium–glucose cotransporter-2 inhibitors (SGLT2is) reduce ventricular arrhythmias and sudden cardiac death is controversial. Ventricular repolarization heterogeneity is associated with ventricular arrhythmias; however, the effect of SGLT2is on ventricular repolarization in patients with heart failure with reduced ejection fraction (HFrEF) has not been fully investigated. We prospectively evaluated 31 HFrEF patients in sinus rhythm who were newly started on dapagliflozin 10 mg/day. Changes in QT interval, corrected QT interval (QTc), QT dispersion (QTD), corrected QTD (QTcD), T peak to T end (TpTe), TpTe/QT ratio, and TpTe/QTc ratio were evaluated at 1-year follow-up. QT interval, QTc interval, QTD, QTcD, TpTe, and TpTe/QTc ratio decreased significantly at 1-year follow-up (427.6 ± 52.6 ms vs. 415.4 ± 35.1 ms;
p
= 0.047, 437.1 ± 37.3 ms vs. 425.6 ± 22.7 ms;
p
= 0.019, 54.1 ± 11.8 ms vs. 47.6 ± 14.7 ms;
p
= 0.003, 56.0 ± 11.2 ms vs. 49.4 ± 12.3 ms;
p
= 0.004, 98.0 ± 15.6 ms vs. 85.5 ± 20.9 ms;
p
= 0.018, and 0.225 ± 0.035 vs. 0.202 ± 0.051;
p
= 0.044, respectively). TpTe/QT ratio did not change significantly (0.231 ± 0.040 vs. 0.208 ± 0.054;
p
= 0.052). QT interval, QTD, and TpTe were significantly reduced 1 year after dapagliflozin treatment in patients with HFrEF. The beneficial effect of dapagliflozin on the heterogeneity of ventricular repolarization may contribute to the suppression of ventricular arrhythmias.
Registry information
https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000049428
. Registry number: UMIN000044902.
Publisher
Springer Japan,Springer Nature B.V
Subject
